Literature DB >> 2138444

Degeneration of pyramidal projection neurons in Huntington's disease cortex.

M Cudkowicz1, N W Kowall.   

Abstract

We examined the distribution of neuropeptide Y immunoreactive local circuit neurons and nonphosphorylated neurofilament (SMI 32) immunoreactive pyramidal projection neurons in superior frontal cortex of patients with Huntington's disease and age-matched control subjects to determine the histological counterpart of increased neuropeptide Y and decrease glutamate concentrations previously found in the cortex of patients with Huntington's disease. We found no difference between the relative density of neuropeptide Y neurons in Huntington's disease and control brains in regions where the relative density of SMI 32 immunoreactive was significantly reduced. Animal studies show that cortical local circuit neurons are resistant to N-methyl-D-aspartate-type excitotoxins such as quinolinic acid. Relative sparing of neuropeptide Y neurons in cerebral cortex with Huntington's disease may, therefore, be a result of excessive N-methyl-D-aspartate receptor activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138444     DOI: 10.1002/ana.410270217

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

1.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 4.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

5.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

6.  Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.

Authors:  P Conforti; D Besusso; V D Bocchi; A Faedo; E Cesana; G Rossetti; V Ranzani; C N Svendsen; L M Thompson; M Toselli; G Biella; M Pagani; E Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

Review 7.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

8.  Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.

Authors:  F R Fusco; Q Chen; W J Lamoreaux; G Figueredo-Cardenas; Y Jiao; J A Coffman; D J Surmeier; M G Honig; L R Carlock; A Reiner
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

9.  Assessment of cortical and striatal involvement in 523 Huntington disease brains.

Authors:  Tiffany C Hadzi; Audrey E Hendricks; Jeanne C Latourelle; Kathryn L Lunetta; L Adrienne Cupples; Tammy Gillis; Jayalakshmi Srinidhi Mysore; James F Gusella; Marcy E MacDonald; Richard H Myers; Jean-Paul Vonsattel
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

10.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.